Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C3

Toxicology and Applied Pharmacology

Volumn 278, Issue 3, 2014, Pages 238-248

  Hofman, Jakub ^a   Malcekova, Beata ^a   Skarka, Adam ^a   Novotna, Eva ^a   Wsol, Vladimir ^a  

^a Charles University in Prague Faculty of Pharmacy   (Czech Republic)

Author keywords

Aldo keto reductase 1C3; Anthracyclines; Drug resistance; Enzyme induction; Metabolism

Indexed keywords

ALDO KETO REDUCTASE 1C3 PROTEIN; DAUNORUBICIN; DAUNORUBICINOL; DOXORUBICIN; DOXORUBICINOL; IDARUBICIN; IDARUBICINOL; PROTEIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BREAST ADENOCARCINOMA; CANCER CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PURIFICATION; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HCT116 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; LUNG CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MCF 7 CELL LINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE DRUG DOSE; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ALDO-KETO REDUCTASE 1C3; ANTHRACYCLINES; DRUG RESISTANCE; ENZYME INDUCTION; METABOLISM;

3-HYDROXYSTEROID DEHYDROGENASES; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; BIOTRANSFORMATION; CARCINOMA; CELL LINE, TUMOR; CELL SURVIVAL; DAUNORUBICIN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ENZYME INDUCTION; ENZYME INHIBITORS; FLAVANONES; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IDARUBICIN; KINETICS; NEOPLASM PROTEINS; OXIDATION-REDUCTION; RECOMBINANT PROTEINS;

EID: 84902305949     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2014.04.027     Document Type: Article

References (50)

1. Adeniji A.O., Chen M., Penning T.M. AKR1C3 as a target in castrate resistant prostate cancer. J. Steroid Biochem. Mol. Biol. 2013, 137:136-149.
2. Ax W., Soldan M., Koch L., Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem. Pharmacol. 2000, 59:293-300.
3. Azzarello J.T., Lin H.K., Gherezghiher A., Zakharov V., Yu Z., Kropp B.P., Culkin D.J., Penning T.M., Fung K.M. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int. J. Clin. Exp. Pathol. 2009, 3:147-155.
4. Bains O.S., Grigliatti T.A., Reid R.E., Riggs K.W. Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J. Pharmacol. Exp. Ther. 2010, 335:533-545.
5. Birtwistle J., Hayden R.E., Khanim F.L., Green R.M., Pearce C., Davies N.J., Wake N., Schrewe H., Ride J.P., Chipman J.K., Bunce C.M. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat. Res. 2009, 662:67-74.
6. Brockmann H., Bauer K. Rhodomycin, ein rotes Antibioticum aus Actinomyceten. Naturwissenschaften 1950, 37:492-493.
7. Brozic P., Turk S., Rizner T.L., Gobec S. Inhibitors of aldo-keto reductases AKR1C1-AKR1C4. Curr. Med. Chem. 2011, 18:2554-2565.
8. Byrns M.C., Duan L., Lee S.H., Blair I.A., Penning T.M. Aldo-keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. J. Steroid Biochem. Mol. Biol. 2010, 118:177-187.
9. Byrns M.C., Jin Y., Penning T.M. Inhibitors of type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3): overview and structural insights. J. Steroid Biochem. Mol. Biol. 2011, 125:95-104.
10. Den Boer M.L., Pieters R., Veerman A.J. Mechanisms of cellular anthracycline resistance in childhood acute leukemia. Leukemia 1998, 12:1657-1670.
11. Desmond J.C., Mountford J.C., Drayson M.T., Walker E.A., Hewison M., Ride J.P., Luong Q.T., Hayden R.E., Vanin E.F., Bunce C.M. The aldo-keto reductase AKR1C3 is a novel suppressor of cell differentiation that provides a plausible target for the non-cyclooxygenase-dependent antineoplastic actions of nonsteroidal anti-inflammatory drugs. Cancer Res. 2003, 63:505-512.
12. Fletcher J.I., Haber M., Henderson M.J., Norris M.D. ABC transporters in cancer: more than just drug efflux pumps. Nat. Rev. Cancer 2010, 10:147-156.
13. Gavelova M., Hladikova J., Vildova L., Novotna R., Vondracek J., Krcmar P., Machala M., Skalova L. Reduction of doxorubicin and oracin and induction of carbonyl reductase in human breast carcinoma MCF-7 cells. Chem. Biol. Interact. 2008, 176:9-18.
14. Heibein A.D., Guo B., Sprowl J.A., Maclean D.A., Parissenti A.M. Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization. BMC Cancer 2012, 12:381.
15. Hoffmann F., Maser E. Carbonyl reductases and pluripotent hydroxysteroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily. Drug Metab. Rev. 2007, 39:87-144.
16. Hofman J., Buncek M., Haluza R., Streinz L., Ledvina M., Cigler P. In vitro transfection mediated by dendrigraft poly(l-lysines): the effect of structure and molecule size. Macromol. Biosci. 2013, 13:167-176.
17. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54(Suppl. 4):1-7.
18. Jansson A.K., Gunnarsson C., Cohen M., Sivik T., Stal O. 17beta-hydroxysteroid dehydrogenase 14 affects estradiol levels in breast cancer cells and is a prognostic marker in estrogen receptor-positive breast cancer. Cancer Res. 2006, 66:11471-11477.
19. Jez J.M., Penning T.M. The aldo-keto reductase (AKR) superfamily: an update. Chem. Biol. Interact. 2001, 130-132:499-525.
20. Jin Y., Penning T.M. Aldo-keto reductases and bioactivation/detoxication. Annu. Rev. Pharmacol. Toxicol. 2007, 47:263-292.
21. Jin J., Krishack P.A., Cao D. Role of aldo-keto reductases in development of prostate and breast cancer. Front. Biosci. 2006, 11:2767-2773.
22. Kassner N., Huse K., Martin H.J., Godtel-Armbrust U., Metzger A., Meineke I., Brockmoller J., Klein K., Zanger U.M., Maser E., Wojnowski L. Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab. Dispos. 2008, 36:2113-2120.
23. Khanim F.L., Hayden R.E., Birtwistle J., Lodi A., Tiziani S., Davies N.J., Ride J.P., Viant M.R., Gunther U.L., Mountford J.C., Schrewe H., Green R.M., Murray J.A., Drayson M.T., Bunce C.M. Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS One 2009, 4:e8147.
24. Krogh-Madsen M., Bender B., Jensen M.K., Nielsen O.J., Friberg L.E., Honore P.H. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemother. Pharmacol. 2012, 69:1155-1163.
25. Kuffel M.J., Reid J.M., Ames M.M. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother. Pharmacol. 1992, 30:51-57.
26. Lin H.K., Steckelbroeck S., Fung K.M., Jones A.N., Penning T.M. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17beta-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004, 69:795-801.
27. Mahadevan D., DiMento J., Croce K.D., Riley C., George B., Fuchs D., Mathews T., Wilson C., Lobell M. Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia. Am. J. Hematol. 2006, 81:779-786.
28. Matsunaga T., Shintani S., Hara A. Multiplicity of mammalian reductases for xenobiotic carbonyl compounds. Drug Metab. Pharmacokinet. 2006, 21:1-18.
29. Miller V.L., Lin H.K., Murugan P., Fan M., Penning T.M., Brame L.S., Yang Q., Fung K.M. Aldo-keto reductase family 1 member C3 (AKR1C3) is expressed in adenocarcinoma and squamous cell carcinoma but not small cell carcinoma. Int. J. Clin. Exp. Pathol. 2012, 5:278-289.
30. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol. Rev. 2004, 56:185-229.
31. Mordente A., Meucci E., Silvestrini A., Martorana G.E., Giardina B. New developments in anthracycline-induced cardiotoxicity. Curr. Med. Chem. 2009, 16:1656-1672.
32. Nakamura Y., Suzuki T., Nakabayashi M., Endoh M., Sakamoto K., Mikami Y., Moriya T., Ito A., Takahashi S., Yamada S., Arai Y., Sasano H. In situ androgen producing enzymes in human prostate cancer. Endocr. Relat. Cancer 2005, 12:101-107.
33. Novotna R., Wsol V., Xiong G., Maser E. Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol. Lett. 2008, 181:1-6.
34. Park A.L., Lin H.K., Yang Q., Sing C.W., Fan M., Mapstone T.B., Gross N.L., Gumerlock M.K., Martin M.D., Rabb C.H., Fung K.M. Differential expression of type 2 3alpha/type 5 17beta-hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system. Int. J. Clin. Exp. Pathol. 2010, 3:743-754.
35. Penning T.M., Byrns M.C. Steroid hormone transforming aldo-keto reductases and cancer. Ann. N. Y. Acad. Sci. 2009, 1155:33-42.
36. Penning T.M., Drury J.E. Human aldo-keto reductases: function, gene regulation, and single nucleotide polymorphisms. Arch. Biochem. Biophys. 2007, 464:241-250.
37. Penning T.M., Steckelbroeck S., Bauman D.R., Miller M.W., Jin Y., Peehl D.M., Fung K.M., Lin H.K. Aldo-keto reductase (AKR) 1C3: role in prostate disease and the development of specific inhibitors. Mol. Cell. Endocrinol. 2006, 248:182-191.
38. Plebuch M., Soldan M., Hungerer C., Koch L., Maser E. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes. Cancer Lett. 2007, 255:49-56.
39. Rizner T.L. Enzymes of the AKR1B and AKR1C subfamilies and uterine diseases. Front. Pharmacol. 2012, 3:34.
40. Rizner T.L., Smuc T., Rupreht R., Sinkovec J., Penning T.M. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol. Cell. Endocrinol. 2006, 248:126-135.
41. Schott B., Robert J. Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture. Biochem. Pharmacol. 1989, 38:4069-4074.
42. Skarka A., Skarydova L., Stambergova H., Wsol V. Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase. Chem. Biol. Interact. 2011, 191:66-74.
43. Skarydova L., Zivna L., Xiong G., Maser E., Wsol V. AKR1C3 as a potential target for the inhibitory effect of dietary flavonoids. Chem. Biol. Interact. 2009, 178:138-144.
44. Smuc T., Rizner T.L. Aberrant pre-receptor regulation of estrogen and progesterone action in endometrial cancer. Mol. Cell. Endocrinol. 2009, 301:74-82.
45. Soldan M., Netter K.J., Maser E. Induction of daunorubicin carbonyl reducing enzymes by daunorubicin in sensitive and resistant pancreas carcinoma cells. Biochem. Pharmacol. 1996, 51:117-123.
46. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., Febbo P.G., Balk S.P. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006, 66:2815-2825.
47. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
48. Tedeschi A., Montillo M., Strocchi E., Cafro A.M., Tresoldi E., Intropido L., Nichelatti M., Marbello L., Barate C., Camaggi C.M., Morra E. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study. Cancer Chemother. Pharmacol. 2007, 59:771-779.
49. Veitch Z.W., Guo B., Hembruff S.L., Bewick A.J., Heibein A.D., Eng J., Cull S., Maclean D.A., Parissenti A.M. Induction of 1C aldoketoreductases and other drug dose-dependent genes upon acquisition of anthracycline resistance. Pharmacogenet. Genomics 2009, 19:477-488.
50. Zhong L., Shen H., Huang C., Jing H., Cao D. AKR1B10 induces cell resistance to daunorubicin and idarubicin by reducing C13 ketonic group. Toxicol. Appl. Pharmacol. 2011, 255:40-47.